ASML Holding NV vs AstraZeneca PLC: Strategic Comparison

This in-depth comparison examines ASML Holding NV and AstraZeneca PLC across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching ASML Holding NV on its own, evaluating AstraZeneca PLC, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between ASML Holding NV and AstraZeneca PLC is widest.

On the headline numbers, ASML Holding NV reports annual revenue of $35.3B against $58.7B for AstraZeneca PLC, while their respective market capitalizations stand at $268.0B and $275.0B. ASML Holding NV is headquartered in Netherlands and AstraZeneca PLC operates from United Kingdom, and those different home markets shape how each company competes.

ASML Holding NV: ASML makes money by selling lithography systems and providing installed-base service, upgrades, software, and field options. Its EUV monopoly creates unusually high strategic importance within the global chip supply chain.

AstraZeneca PLC: AstraZeneca makes money primarily from patented prescription medicines, plus alliance and collaboration revenue. Its scale depends on clinical development, regulatory approvals, market access, lifecycle management, and global commercial execution.

ASML Holding NV and AstraZeneca PLC pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between ASML Holding NV and AstraZeneca PLC.

ASML Holding NV business model: Building one requires components sourced from more than 5,000 suppliers across 16 countries, assembled through a process so intricate that delivery, installation, and commissioning at a customer's fabrication plant takes months. EUV systems represent the apex of ASML's product portfolio and the locus of its pricing power. Instead, ASML sells performance upgrades — enhanced throughput, improved overlay accuracy, expanded process windows — as separately licensed software and hardware packages that customers purchase over the machine's operational lifetime. ASML's pricing power is extraordinary by any industrial standard, and it derives directly from the company's monopoly position. This allows ASML to maintain gross margins on EUV systems that consistently exceed 50 percent and to set pricing that reflects the extraordinary economic value the equipment creates for customers. The problem is, ASML captures a small but growing fraction of this value through its pricing. China's share of ASML's total revenue, which reached approximately 29 percent in the first half of 2023, has been progressively curtailed since the Dutch government declined to renew ASML's export license for EUV systems in 2019. Each new generation of EUV technology commands higher pricing, drives higher service revenue, and further widens the technological gap between ASML and any theoretical competitor.

AstraZeneca PLC business model: The company maintains a harmonised listing on the London Stock Exchange, Nasdaq Stockholm, and the New York Stock Exchange, and sells medicines in more than 125 countries. Collaboration Revenue, which includes milestone payments, upfront fees from partnership arrangements, and royalties on out-licensed intellectual property, added $1.1 billion in 2025. Surprisingly, the rare disease market's high barriers to entry, including complex biologics manufacturing, small patient populations, and specialized diagnostic requirements, protect AstraZeneca's pricing power but also limit the addressable market size. These targets require not merely product success but also commercial execution, pricing negotiation, and reimbursement approval across dozens of regulatory jurisdictions. Here's why: the merger also triggered regulatory scrutiny, with the U.S. Federal Trade Commission requiring the divestiture of Zeneca's rights to levobupivacaine, a long-acting local anesthetic, to preserve competition in a market where Astra was the dominant supplier.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of ASML Holding NV stack up against those of AstraZeneca PLC.

ASML Holding NV competitive advantage: This service business is characterized by very high switching costs: a chipmaker cannot simply swap out lithography equipment mid-production without catastrophic disruption. The company's headquarters in Veldhoven, adjacent to the Dutch city of Eindhoven, reflects its roots in the Philips industrial ecosystem that made the southern Netherlands a European technology hub in the twentieth century. The physics challenges, the optical engineering requirements, and the supplier ecosystem limitations that China faces are not primarily financial obstacles; they are time and knowledge obstacles that money alone cannot solve on any commercially relevant timeline. ASML's competitive advantage is perhaps the most formidable in the global technology industry, resting on a combination of accumulated technological know-how, supplier ecosystem lock-in, customer switching costs, and regulatory moats that collectively make replication by any competitor — whether private, state-sponsored, or otherwise — extraordinarily difficult. The technological core of ASML's advantage is its mastery of EUV lithography, a technology that the company spent over 20 years and billions of dollars developing before shipping its first commercial EUV machine in 2017. The Carl Zeiss SMT relationship deserves particular emphasis as a competitive moat. ASML's customer relationships also create powerful demand-side moats. This technical advantage was real but not significant, and ASML spent its first several years fighting for every customer order, often competing on price to compensate for its lack of brand recognition.

AstraZeneca PLC competitive advantage: AstraZeneca's competitive position is strengthened by its integrated oncology ecosystem, rare disease complement platform, and emerging presence in weight management and cell therapy. The DAPA-HF and DAPA-CKD trials gave Farxiga a first-mover advantage in heart failure that Jardiance has since matched, but Farxiga's earlier approval and broader label have maintained its leadership position. The gross profit margin on Product Sales was 84% in 2025, reflecting higher manufacturing costs and product mix shifts, with the company targeting margin improvement through scale efficiencies and biologics mix expansion. AstraZeneca's single most defensible competitive moat is its integrated oncology ecosystem, which combines targeted small molecules, immuno-oncology biologics, antibody-drug conjugates, and radiopharmaceuticals into a portfolio that no competitor can replicate in under a decade. The company's R&D productivity metrics support this moat: AstraZeneca achieved 74 regulatory events and 24 pipeline progression events in 2024, with 16 positive Phase III readouts in 2025 and a pipeline of 186 projects including 19 new molecular entities in late-stage development. The company's geographic diversification further strengthens the moat: AstraZeneca is the number one pharmaceutical company in Emerging Markets, including China, and holds top-three positions in Europe and Japan, meaning that no single market disruption can destabilize the overall enterprise. The success of these bets depends on flawless execution across clinical development, regulatory approval, manufacturing scale-up, and commercial launch, a sequence of complex activities where any single failure could delay revenue targets by years. The spinoff gave Zeneca independence, a strong oncology portfolio, and the need to find scale it couldn't achieve alone in an industry that was consolidating globally.

Future prospects matter as much as current results. The growth strategies below explain how ASML Holding NV and AstraZeneca PLC each plan to expand from here.

ASML Holding NV growth strategy: ASML's growth strategy centers on EUV capacity, High-NA EUV adoption, installed-base service upgrades, deep supplier coordination, and long-term demand from leading-edge logic and memory customers.

AstraZeneca PLC growth strategy: AstraZeneca's growth strategy centers on oncology expansion, rare disease from Alexion, cardiovascular and renal medicines, respiratory and immunology launches, pipeline execution, and manufacturing/R&D investment.

A closer look at the financial trajectory of ASML Holding NV and AstraZeneca PLC rounds out the comparison.

ASML Holding NV: ASML reported EUR32.7B in FY2025 total net sales, EUR9.6B in net income, a 52.8% gross margin, and EUR38.8B of backlog at year-end. Using CorpDigest's USD convention, those figures are shown as about $35.3B of revenue and $10.4B of net income. The key financial drivers are EUV system demand, DUV resilience, installed-base services, High-NA adoption, and export-control limits.

AstraZeneca PLC: AstraZeneca reported FY2025 total revenue of $58.739B, up 9% at actual exchange rates, and profit for the year of $10.233B. Growth was driven by oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare disease medicines. The strategic questions are pipeline productivity, patent exposure, China and U.S. policy risk, and execution toward the company's 2030 revenue ambitions.